@prefix biolink: . @prefix ns1: . @prefix this: . @prefix sub: . @prefix schema: . @prefix np: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix nkg: . @prefix dct: . @prefix rdf: . @prefix npx: . @prefix prov: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { biolink:category biolink:Disease . sub:association rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a rdf:Statement; rdfs:label "Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12)"; biolink:has_population_context sub:cohort; biolink:provided_by ; biolink:publications ; biolink:relation nkg:OffLabelIndication . sub:cohort rdfs:label "Children and adolescents"; schema:requiredMaxAge "17"; schema:requiredMinAge "12"; biolink:category biolink:Cohort . biolink:category biolink:Drug . } sub:provenance { sub:assertion prov:generatedAtTime "2021-08-24T15:53:47.2920" . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB"; npx:hasSignature "Ls/zauvLpbfRhYdRIwdUmPe+S/Sz8Wecb4rRMHeP7+1mnE7/oyM34AF8fy8bNyQBIPfc4T1D8ezK2X30IZSdrRx8EMFv701bE0cBwK0BUUUNG/AQqSkhJ4JW0EpBS+ubbFENYEIi/woCmYMMf9YrbYjUrDRIq8maq6U18o7iFeg="; npx:hasSignatureTarget this: . this: dct:created "2021-09-13T13:14:11.326+02:00"^^xsd:dateTime; dct:creator orcid:0000-0002-7641-6446; npx:supersedes ; prov:generatedAtTime "2021-08-24T15:53:47.2920"; prov:wasAttributedTo orcid:0000-0002-7641-6446; ns1:wasCreatedFromProvenanceTemplate ; ns1:wasCreatedFromPubinfoTemplate , , ; ns1:wasCreatedFromTemplate . }